Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Summary by The Manila Times
Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) - - Additional data...

1 Articles

The Manila TimesThe Manila Times
Lean Right

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) - - Additional data...

·Manila, Philippines (the)
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Tuesday, May 5, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

Manila icon

Manila

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal